ADVFN ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Innocare Pharma Ltd (PK)

Innocare Pharma Ltd (PK) (INCPF)

1,55
0,00
(0,00%)
Geschlossen 24 Juni 10:00PM

Innocare Pharma Ltd (PK) (INCPF) Aktie

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Premium

Wichtige Statistiken und Details

Current Price
1,55
( - )
Gebot
0,0001
Fragen
197.601,94
Volumen
-
0,00 Tagesbereich 0,00
1,55 52-Wochen-Bereich 3,26
Marktkapitalisierung
Handelsende
1,55
Handelsbeginn
-
Letzte Trade
Letzter Handelszeitpunkt
Finanzvolumen
-
VWAP
-
Durchschnittliches Volumen (3 Mio.)
US$ 8.671.809
Ausgegebene Aktien
1.695.928.424
Dividendenrendite (LTM)
Kurs-Gewinn-Verhältnis
21,54
Gewinn pro Aktie (EPS)
0,43
Erlöse (LTM)
2,52B
Nettogewinn (LTM)
730,32M

Über Innocare Pharma Ltd (PK)

InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China. The company develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymph... InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China. The company develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom’s macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. It also developing ICP-B02 to treat CD20+B-cell malignancies; ICP-B05 to treat hemato-oncology; ICP-248 to treat chronic lymphocytic leukemia; ICP-332 to treat atopic dermatitis; ICP-488 to treat psoriasis; ICP-538 to treat autoimmune diseases; zurletrectinib (ICP-723) to treat neurotrophic tyrosine receptor kinase fusion positive cancers; ICP-189 to treat non-small cell lung cancer; and ICP-B05 to treat solid tumor. InnoCare Pharma Limited was incorporated in 2015 and is headquartered in Beijing, China. Mehr anzeigen

Sektor
Healthcare
Branche
Pharmaceuticals
Hauptsitz
Beijing, China
Gegründet
2026
Innocare Pharma Ltd (PK) is listed in the Healthcare sector of the OTC Markets with ticker INCPF. The last closing price for Innocare Pharma (PK) was US$1,55. Over the last year, Innocare Pharma (PK) shares have traded in a share price range of US$ 1,55 to US$ 3,26.

Innocare Pharma (PK) currently has 1.695.928.424 shares in issue. The market capitalisation of Innocare Pharma (PK) is US$2,63 billion. Innocare Pharma (PK) has a price to earnings ratio (PE ratio) of 21.54.
Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
10000000CS
40000000CS
12001.551.551.5500CS
26-0.5-24.39024390242.052.051.552501.8CS
52-1.71-52.45398773013.263.261.551001.83818182CS
156-1.71-52.45398773013.263.261.55761.83818182CS
260-2.15-58.10810810813.73.721.552733.26712871CS

INCPF - Frequently Asked Questions (FAQ)

What is the current Innocare Pharma Ltd (PK) share price?
The current share price of Innocare Pharma Ltd (PK) is US$ 1,55
How many Innocare Pharma Ltd (PK) shares are in issue?
Innocare Pharma Ltd (PK) has 1.695.928.424 shares in issue
What is the market cap of Innocare Pharma Ltd (PK)?
The market capitalisation of Innocare Pharma Ltd (PK) is USD 2,63B
What is the 1 year trading range for Innocare Pharma Ltd (PK) share price?
Innocare Pharma Ltd (PK) has traded in the range of US$ 1,55 to US$ 3,26 during the past year
What is the PE ratio of Innocare Pharma Ltd (PK)?
The price to earnings ratio of Innocare Pharma Ltd (PK) is 21,54
What is the cash to sales ratio of Innocare Pharma Ltd (PK)?
The cash to sales ratio of Innocare Pharma Ltd (PK) is 7,83
What is the registered address of Innocare Pharma Ltd (PK)?
The registered address for Innocare Pharma Ltd (PK) is Building 8, Beijing, 102206
What is the Innocare Pharma Ltd (PK) website address?
The website address for Innocare Pharma Ltd (PK) is www.innocarepharma.com
Which industry sector does Innocare Pharma Ltd (PK) operate in?
Innocare Pharma Ltd (PK) operates in the Pharmaceuticals sector

INCPF Trades

Mehr

Trades verzögert

Um Echtzeit-Trades zu erhalten, aktualisieren Sie Ihr Konto

Auf Echtzeit aktualisieren
Keine Diskussionen Gefunden.
Neuen Thread Erstellen